Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid

被引：0
|
作者：
Kridin, Khalaf [1 ,2 ,3 ]
Hammers, Christoph M. [1 ,4 ]
机构：
[1] Univ Lubeck, Lubeck Inst Expt Dermatol LIED, Lubeck, Germany
[2] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel
[3] Barch Padeh Med Ctr, Unit Dermatol & Skin Res Lab, Poriya, Israel
[4] Christian Albrechts Univ Kiel, Dept Dermatol, Kiel, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 06期
关键词：
D O I：
10.1111/bjd.21882
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：843 / 844
页数：2
相关论文
共 50 条
  • [21] Case of dipeptidyl peptidase 4 inhibitor-associated bullous pemphigoid that developed after a scabies infestation
    Iriki, Hisato
    Adachi, Takahiro
    Matsuda, Hideshi
    Chinen, Katsuya
    Arakawa, Hiroki
    Yamagami, Jun
    Nishie, Wataru
    Yokouchi, Mariko
    JOURNAL OF DERMATOLOGY, 2020, 47 (07): : E258 - E260
  • [22] Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis
    Wang, Hanping
    Guo, Xiaoxiao
    Zhou, Jiaxin
    Li, Yue
    Duan, Lian
    Si, Xiaoyan
    Zhang, Li
    Liu, Xiaowei
    Wang, Mengzhao
    Shi, Juhong
    Zhang, Li
    THORACIC CANCER, 2020, 11 (01) : 191 - 197
  • [23] Antibiotic exposure for immune checkpoint inhibitor induced bullous pemphigoid associated with worse outcomes
    Fay, C. J.
    Awh, K.
    Said, J. T.
    Allais, B. S.
    LeBoeuf, N.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S95 - S95
  • [24] Immune checkpoint inhibitor-associated autoimmune encephalitis-an emerging cause for encephalitis
    Herath, Tharuka Milinda
    Mbydeen, Tsneem H. S.
    Saleh, May
    Wimalaratna, Sunil Wimalaratne Sunil
    BMJ CASE REPORTS, 2024, 17 (06)
  • [25] Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis
    Hanson, Brooke
    Spector, Logan G.
    Boull, Christina
    Polcari, Ingrid
    Hook, Kristen
    Maguiness, Sheilagh
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (02) : 501 - 504
  • [26] Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid with oral mucosal lesions: A case report
    Iguchi, Naohiko
    Minabe, Masaki
    Akira, Yuria
    Inada, Junichiro
    Akiyama, Yurie
    Hashimoto, Kazuhiko
    Takahashi, Shinichi
    Nomura, Takeshi
    Kouno, Michiyoshi
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY MEDICINE AND PATHOLOGY, 2023, 35 (06) : 559 - 563
  • [27] Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis
    Maki, Nobuki
    Nishie, Wataru
    Takazawa, Maya
    Kakurai, Maki
    Yamada, Tomoko
    Umemoto, Naoka
    Kawase, Masaaki
    Izumi, Kentaro
    Shimizu, Hiroshi
    Demitsu, Toshio
    JOURNAL OF DERMATOLOGY, 2018, 45 (05): : 600 - 602
  • [28] Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities
    Wu, Nan-Chun
    Feng, Yin-Hsun
    Kuo, Yu Hsuan
    Chen, Wei-Yu
    Wu, Hong-Chang
    Huang, Chien-Tai
    Wang, Wen-Ching
    Kang, Nai-Wen
    Shih, Jhih-Yuan
    Chen, Zhih-Cherng
    Chang, Wei-Ting
    ACTA CARDIOLOGICA SINICA, 2022, 38 (01) : 39 - 46
  • [29] Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics
    Nishie, Wataru
    IMMUNOLOGICAL MEDICINE, 2019, 42 (01) : 22 - 28
  • [30] Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: a single-centre study
    Hayashi, M.
    Tsunoda, T.
    Sato, F.
    Yaguchi, Y.
    Igarashi, M.
    Izumi, K.
    Nishie, W.
    Ishii, N.
    Okamura, K.
    Suzuki, T.
    Hashimoto, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (03) : 806 - 807
12345